Last reviewed · How we verify

NCT05158114

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Testicular Injury and Oligospermia

Withdrawn Phase 1 Last updated 6 April 2025
What this trial tests

Phase 1 trial testing AlloRx in Testicular Injury. Withdrawn.

Timeline
3 April 2025
Primary endpoint
3 April 2025
3 April 2025

Quick facts

Lead sponsorThe Foundation for Orthopaedics and Regenerative Medicine
PhasePhase 1
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date3 April 2025
Primary completion3 April 2025
Estimated completion3 April 2025
Sites1 location across Antigua and Barbuda

Drugs / interventions tested

Conditions studied

Sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Who can join

Eligibility, any sex, with Testicular Injury or Oligospermia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Testicular Injury and Oligospermia

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Effects of clinical medications on male fertility and prospects for stem cell therapy.
    Mo P, Zhao Z, Ke X, Fan Y, et al · · 2023 · cited 5× · PMID 37791073 · DOI 10.3389/fcell.2023.1258574

Verify or expand the search:

Other trials of AlloRx

Trials testing the same drug.

Other The Foundation for Orthopaedics and Regenerative Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05158114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing